thumbnail image
HomeAbout UsPortfolio
NewsContact Us
中文
HomeAbout UsPortfolioNewsContact Us
HomeAbout UsPortfolio
NewsContact Us
中文
  • POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES

    Domain expertise, global resource, long-term capital

  • PORTFOLIO NEWS

    GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
    September 15, 2026
    Trispecific TCE targeting T cells and two tumour antigens has potential for differentiated...
    Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
    June 29, 2026
    Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in...
    IMPACT Therapeutics (07630.HK) Lists on HKEX Main Board
    May 13, 2026
    May 13, 2026 – IMPACT Therapeutics, Inc. (“IMPACT Therapeutics” or the “Company”), a commercial...
    More Posts

Locations

Hong Kong

Room 606-7, St George's Building, 2 Ice House Street, Central, Hong Kong

Shanghai

Room 2909-17, Infinitus Tower, 168 Hubin Road, Huangpu, Shanghai

US

2735 Sand Hill Road, Suite 210, Menlo Park, CA 94025

copyright © 2018 LAV all rights reserved.

沪公网安备 31010102005458号
|
沪ICP备12003647号-2
    LAV
    LAV is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
    https://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More